Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
CVT-12012
Cat. No.:
OB0225LY-0229
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
CVT-12012 is a stearoyl-CoA desaturase inhibitor.
Synonym:
1018675-35-8; 2-Hydroxy-N-(2-(3-methyl-2-oxo-7-(((3-(trifluoromethyl)phenyl)methyl)amino)-1,2-dihydroquinoxalin-1-yl)ethyl)acetamide; 2-Hydroxy-N-(2-(3-methyl-2-oxo-7-((3-(trifluoromethyl)benzyl)amino)quinoxalin-1(2H)-yl)ethyl)acetamide; Acetamide, 2-hydroxy-N-(2-(3-methyl-2-oxo-7-(((3-(trifluoromethyl)phenyl)methyl)amino)-1(2H)-quinoxalinyl)ethyl)-
CAS No.:
1018675-35-8
Compound CID:
25195516
Formula:
C21H21F3N4O3
Formula Weight:
434.41
Specification
Relative Density:
1.37 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
CVT-12012 can be used to study inflammatory responses or play an important role in autoimmune disease models.
Library Information
Targets:
Stearoyl-CoA desaturase (SCD) family
Pathways:
Metabolism
Plate Number:
AOCL-3
Plate Location:
h3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
125 mg/mL; 287.75 mM
